Centogene
Twist Bioscience, Centogene Partner on NGS-Based Rare Disease Genetic Testing
The partners will design multiple assay kits in an attempt to make genetic testing for rare diseases more accessible to patients.
Centogene Q2 Revenues Continue to Benefit From COVID-19 Testing as Core Business Starts to Recover
The German rare disease diagnostics company had €51.9 million in Q2 revenues, significantly beating the average Wall Street estimate.
Centogene Q1 Revenues Grow More Than Fivefold Driven by COVID-19 Testing
Core diagnostic testing revenues were €6.4 million, down 15 percent year over year, while pharmaceutical revenues totaled €3.6 million, down 22 percent.
In Brief This Week: PerkinElmer, OraSure Technologies, LabCorp, Molzym, UniLabs, and More
News items for the in vitro diagnostics industry for the week of May 10, 2021.
Centogene Q4 Revenues Grow Almost Fivefold, Driven by COVID-19 Testing
For 2020, the company reported €128.4 million in revenues, including €89.3 million from COVID-19 testing, more than doubling its 2019 revenues of €48.8 million.
Dec 16, 2020
Centogene Q3 Revenues Triple on COVID-19 Testing
Sep 23, 2020
Centogene Reports 13 Percent Decline in Q2 Revenues
Jul 10, 2020
Centogene to Raise $28M in Public Stock Offering
Jun 15, 2020
Centogene Q1 Revenues Increase 13 Percent
Apr 23, 2020